Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy

被引：0
作者：
Vienna Ludovini
Cinzia Antognelli
Antonio Rulli
Jennifer Foglietta
Lorenza Pistola
Rulli Eliana
Irene Floriani
Giuseppe Nocentini
Francesca Romana Tofanetti
Simonetta Piattoni
Elisa Minenza
Vincenzo Nicola Talesa
Angelo Sidoni
Maurizio Tonato
Lucio Crinò
Stefania Gori
机构：
[1] Azienda Ospedaliera of Perugia,Medical Oncology Division, S. Maria della Misericordia Hospital
[2] University of Perugia,Department of Experimental Medicine
[3] University of Perugia,Breast Unit, Department of Surgical
[4] Istituto di Ricerche Farmacologiche “Mario Negri”,Oncology Department, IRCCS
[5] University of Perugia,Section of Pharmacology, Department of Medicine
[6] University of Perugia,Haematology Department
[7] “S. Maria” Hospital,Medical Oncology Division
[8] Medical School,Department of Experimental Medicine, Section of Anatomic and Histology
[9] University of Perugia,Medical Oncology, Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST)
[10] Umbria Regional Cancer Network,Medical Oncology
[11] IRCCS,undefined
[12] SacroCuore-Don Calabria Hospital,undefined
来源：
BMC Cancer | / 17卷
关键词：
Early breast cancer; Polymorphisms; Adjuvant chemotherapy; Toxicity; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 283 条
  • [1] Parkin DM(2005)Global cancer statistics, 2002 CA Cancer J Clin 55 74-108
  • [2] Bray F(2004)The curability of breast cancer and the treatment of advanced disease Eur J Nucl Med Mol Imaging 31 S149-S161
  • [3] Ferlay J(1988)Combination adjuvant chemotherapy for node-positive breast cancer inadequacy of a single erioperative cycle N Engl J Med 319 677-683
  • [4] Pisani P(1992)Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women Lancet 339 1-15
  • [5] Guarneri V(1998)Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930-942
  • [6] Conte PF(1995)Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks Mutat Res 330 115-181
  • [7] Anderson D(2003)5-fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 3 330-338
  • [8] Bishop JB(2002)Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assay Teratog Carcinog Mutagen 22 13-30
  • [9] Colin Garner R(2006)Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients the FNCLCC PACS 01 Trial J Clin Oncol 24 5664-5671
  • [10] Ostrosky-Wegman P(2006)Frequency and cost of chemotherapyrelated serious adverse effects in a population sample of women with breast cancer J Natl Cancer Inst 98 1108-1117
12345678910